Search Result

Results for "

bone resorption

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adrenergic Receptor (1) Antibiotic (1) Apoptosis (8) Autophagy (1) Bacterial (2) Btk (1) CaSR (1) Cathepsin (4) CGRP Receptor (2) COX (1) CXCR (1) Drug Metabolite (1) Endogenous Metabolite (5) Estrogen Receptor/ERR (2) Fungal (2) GABA Receptor (1) Integrin (4) Isotope-Labeled Compounds (2) LXR (1) Nuclear Factor of activated T Cells (NFAT) (1) Parasite (1) PKC (1) PROTACs (1) Proton Pump (2) PTHR (2) RANKL/RANK (2) Thyroid Hormone Receptor (3) VD/VDR (4)
By Research Areas:	Cancer (16) Cardiovascular Disease (6) Endocrinology (3) Infection (3) Inflammation/Immunology (11) Metabolic Disease (29) Neurological Disease (1)

By Targets:

Adrenergic Receptor (1)

Antibiotic (1)

Apoptosis (8)

Autophagy (1)

Bacterial (2)

Btk (1)

CaSR (1)

Cathepsin (4)

CGRP Receptor (2)

COX (1)

CXCR (1)

Drug Metabolite (1)

Endogenous Metabolite (5)

Estrogen Receptor/ERR (2)

Fungal (2)

GABA Receptor (1)

Integrin (4)

Isotope-Labeled Compounds (2)

LXR (1)

Nuclear Factor of activated T Cells (NFAT) (1)

Parasite (1)

PKC (1)

PROTACs (1)

Proton Pump (2)

PTHR (2)

RANKL/RANK (2)

Thyroid Hormone Receptor (3)

VD/VDR (4)

By Research Areas:

Cancer (16)

Cardiovascular Disease (6)

Endocrinology (3)

Infection (3)

Inflammation/Immunology (11)

Metabolic Disease (29)

Neurological Disease (1)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10294

Relacatib SB-462795	Cathepsin	Metabolic Disease Cancer
Relacatib (SB-462795) is a novel, potent, and orally active inhibitor of human cathepsins K, L, and V with K_i values of 41 pM, 68 pM, and 53 pM, respectively. Relacatib inhibits endogenous cathepsin K in situ in human osteoclasts and human osteoclast-mediated bone resorption with IC₅₀ values of 45 nM and 70 nM, respectively. Relacatib inhibits bone resorption in vitro in human tissue as well as in cynomolgus monkeys in vivo .

HY-B0657

Clodronic acid Clodronate	Others	Others
Clodronic acid is an orally active bisphosphonate, which is used for researching osteoporosis and diseases associated with excessive bone resorption. Clodronic acid inhibits bone resorption through induction of osteoclast apoptosis. Clodronic acid is effective in the maintenance or improvement of bone mineral density .

HY-122082

Methopterin	Others	Inflammation/Immunology
Methopterin inhibits osteoclasts proliferation. Methopterin inhibits the activation and bone resorption function of osteoclasts, and induced osteoclasts apoptosis .

HY-P1288

Protein Kinase C (530-558) PKC fragment (530-558)	PKC	Others
Protein Kinase C (530-558), a peptide fragment of protein kinase C (PKC), is a potent PKC activator. Protein Kinase C (530-558) significantly inhibits osteoclastic bone resorption .

HY-113403

Pyridinoline

Endogenous Metabolite Others

Pyridinoline, a fluorescent material, is a bone resorption biomarker. Pyridinoline also is a type crosslink of collagen .

Pyridinoline	Endogenous Metabolite	Others
Pyridinoline, a fluorescent material, is a bone resorption biomarker. Pyridinoline also is a type crosslink of collagen .

HY-N9331

Cimicifugoside H-1 Cimicidanol-3-O-β-d-xyloside	Others	Metabolic Disease
Cimicifugoside H-1, a cyclolanostanol xyloside, is a major constituent of C. foetida L. extract. Cimicifugoside H-1 inhibits bone resorption and ovariectomy-induced bone loss .

HY-P2273

Calcitonin (human)	CGRP Receptor	Metabolic Disease
Calcitonin (human) is a hypocalcemic hormone. Calcitonin can lower blood calcium levels and inhibit bone resorption. Calcitonin can be used in hypercalcemia or osteoporosis research .

HY-P1418

DPC-AJ1951	Thyroid Hormone Receptor	Endocrinology
DPC-AJ1951, a 14 amino acid peptide that acts as a potent agonist of the parathyroid hormone (PTH)/PTH-related peptide receptor (PPR). And characterized the activity of DPC-AJ1951 in ex vivo and in vivo assays of bone resorption .

HY-P1418A

DPC-AJ1951 TFA	Thyroid Hormone Receptor	Endocrinology
DPC-AJ1951 TFA, a 14 amino acid peptide that acts as a potent agonist of the parathyroid hormone (PTH)/PTH-related peptide receptor (PPR). And characterized the activity of DPC-AJ1951 TFA in ex vivo and in vivo assays of bone resorption .

HY-162280

PROTAC BTK Degrader-9	PROTACs RANKL/RANK Nuclear Factor of activated T Cells (NFAT) Btk	Cancer
PROTAC BTK Degrader-9 (compound 23) is a PROTAC degrader that effectively targets BTK. PROTAC BTK Degrader-9 downregulates the BTK-PLCγ2-Ca ²⁺-NFATc1 signaling pathway activated by RANKL. Thus, PROTAC BTK Degrader-9 was able to inhibit osteoclastogenesis and attenuate alveolar bone resorption in a mouse periodontitis model .

HY-110318

VUF11207 fumarate 1 Publications Verification	CXCR	Inflammation/Immunology Cancer
VUF11207 fumarate is a CXCR7 agonist that binds specifically to CXCR7. VUF11207 fumarate reduces CXCL12-mediated osteoclastogenesis and bone resorption by inhibiting ERK phosphorylation .

HY-114275

Justicidin B	Fungal Parasite Apoptosis	Infection Cardiovascular Disease Cancer
Justicidin B is a potent anticancer lignan and proapoptotic agent. Justicidin B is also a bone resorption inhibitor, and has strong antiviral, fungicidal, antiprotozoal effects. Justicidin B significantly inhibits platelet aggregation .

HY-N6084

Humulone α-Lupulic acid	COX GABA Receptor Apoptosis	Cardiovascular Disease
Humulone (α-Lupulic acid), a prenylated phloroglucinol derivative, is a potent cyclooxygenase-2 (COX-2) inhibitor. Humulone acts as a positive modulator of GABA_A receptor at low micromolar concentrations. Humulone is an inhibitor of bone resorption. Humulone possesses antioxidant, anti-angiogenic and apoptosis-inducing properties .

HY-P0322

GRGDSPK EMD 56574	Integrin	Cardiovascular Disease Metabolic Disease
GRGDSPK (EMD 56574) is a peptide incluing Arg-Gly-Asp (RGD). GRGDSPK (EMD 56574) is an competitive and reversible inhibitory peptide for inhibiting integrin-fibronectin binding. GRGDSPK is used to study the role of integrins in bone formation and resorption .

HY-103352

L-006235 L-235	Cathepsin	Metabolic Disease
L-006235 (L-235) is a potent, selective, reversible and orally active inhibitor of cathepsin K, with an IC₅₀ of 5 nM in bone resorption assay. L-006235 shows selectivity for cathepsin K (K_i=0.2 nM) over cathepsin B, cathepsin L, and cathepsin S (K_i=1, 6, and 47 μM, respectively). L-006235 can reduce collagen degradation and prevent bone loss .

HY-P0322A

GRGDSPK TFA EMD 56574 TFA	Integrin	Cardiovascular Disease Metabolic Disease
GRGDSPK TFA (EMD 56574 TFA) is a peptide incluing Arg-Gly-Asp (RGD). GRGDSPK TFA is an competitive and reversible inhibitory peptide for inhibiting integrin-fibronectin binding. GRGDSPK TFA is used to study the role of integrins in bone formation and resorption .

HY-129337

Reveromycin A	Antibiotic Fungal Apoptosis	Infection Cancer
Reveromycin A, a benzoquinoid antibiotic isolated from the genus Streptomyces, is a selective inhibitor of protein synthesis in eukaryotic cells. Reveromycin A inhibits bone resorption by inducing apoptosis specifically in osteoclasts. Reveromycin A has antiproliferative activity against tumor cell lines and antifungal activity .

HY-135594

4'-Raloxifene-β-D-glucopyranoside	Estrogen Receptor/ERR	Metabolic Disease
4'-Raloxifene-β-D-glucopyranoside, a metabolite of Raloxifene, is a benzothiophene glucuronidated at the 4' postion. 4'-Raloxifene-β-D-glucopyranoside is a selective and orally active estrogen receptor antagonist. 4'-Raloxifene-β-D-glucopyranoside can be used for inhibiting bone loss and resorption, and lowering lipid levels. 4'-Raloxifene-β-D-glucopyranoside, example 5, is extracted from patent US5567820A .

HY-123370

FR-167356	Proton Pump	Metabolic Disease Cancer
FR-167356 is a potent, orally active and selective vacuolar ATPase inhibitor with IC₅₀ values of 170, 220, 370, and 1200 nM for osteoclast plasma membranes, macrophage microsomes, renal brush border membranes, and liver lysosomal membranes, respectively. FR-167356 inhibits bone resorption and ovariectomy-induced bone loss .

HY-152262

LXRβ agonist-4	LXR	Inflammation/Immunology
LXRβ agonist-4 is a potent, orally active Liver X receptors (LXRs) agonist with an IC₅₀ value of 0.0078 μM for LXRβ. LXRβ agonist-4 inhibits RANKL-induced osteoclast differentiation and bone resorption. LXRβ agonist-4 can be used in research of osteoporosis .

HY-149852

Anti-osteoporosis agent-3	Others	Inflammation/Immunology
Anti-osteoporosis agent-3 (Compound 11), a PMSA derivative, is an anti-osteoporosis agent. Anti-osteoporosis agent-3 inhibits osteoclastogenesis with an IC₅₀ value of 322.9 nM in vitro. Anti-osteoporosis agent-3 also blocks the formation of F-action belts and bone resorption .

HY-126825

NE21650	Others	Metabolic Disease
NE21650 potently inhibits farnesyl diphosphate (FPP) synthase. NE21650 is a weak inhibitor of isopentenyl diphosphate (IPP) isomerase. NE21650 is a potent inhibitor of protein prenylation in osteoclasts and macrophages and bone resorption in vitro .

HY-12398

TEI-9647	VD/VDR	Metabolic Disease Inflammation/Immunology
TEI-9647, a Vitamin D₃ Lactone analogue, is a potent and specific vitamin D receptor (VDR) antagonist. TEI-9647 inhibits VDR/VDRE-mediated genomic actions of 1α,25(OH)₂D₃. TEI-9647 inhibits bone resorption and HL-60 cell differentiation induced by of 1α,25(OH)₂D₃. TEI-9647 has the potential for suppressing the excessive bone resorption and osteoclast formation in Paget's disease .

HY-A0020

Eldecalcitol 1 Publications Verification ED-71; 2-(3-hydroxypropoxy)-1,25-dihydroxyvitamin D3	VD/VDR Apoptosis	Metabolic Disease Inflammation/Immunology Cancer
Eldecalcitol (ED-71) is an orally active vitamin D3 analogue, inhibits bone resorption and increases bone mineral density. Eldecalcitol (ED-71) displays anti-tumor effect and inhibits cell proliferation, migration and induces apoptosis by suppressing GPx-1 .

HY-N0094

Ipriflavone

2 Publications Verification

Others Metabolic Disease Cancer

Ipriflavone is a synthetic isoflavone derivative used to suppress bone resorption.
HY-B0119

Risedronic acid sodium

Risedronate sodium
Others Others

Risedronic acid sodium is a pyridinyl biphosphonate which inhibits osteoclast-mediated bone resorption.

Ipriflavone 2 Publications Verification	Others	Metabolic Disease Cancer
Ipriflavone is a synthetic isoflavone derivative used to suppress bone resorption.

Risedronic acid sodium Risedronate sodium	Others	Others
Risedronic acid sodium is a pyridinyl biphosphonate which inhibits osteoclast-mediated bone resorption.

HY-113230

Galactosylhydroxylysine	Endogenous Metabolite	Metabolic Disease
Galactosylhydroxylysine is a component of bone collagen produced by post-translational glycosylation of hydroxylysine. Galactosylhydroxylysine is released during bone resorption and has been shown to be elevated in metabolic bone loss .

HY-113230B

Galactosylhydroxylysine hydrochloride	Endogenous Metabolite	Metabolic Disease
Galactosylhydroxylysine hydrochloride is a component of bone collagen produced by post-translational glycosylation of hydroxylysine. Galactosylhydroxylysine hydrochloride is released during bone resorption and has been shown to be elevated in metabolic bone loss .

HY-B0148

Risedronic acid 1 Publications Verification Risedronate	Others	Others
Risedronic acid (Risedronate ) is a pyridinyl biphosphonate which inhibits osteoclast-mediated bone resorption.

HY-P0090

Calcitonin (salmon) 1 Publications Verification Salmon calcitonin	CGRP Receptor	Cancer
Calcitonin salmon, a calcium regulating hormone, is a dual-action amylin and calcitonin receptor agonist, could stimulate bone formation and inhibit bone resorption.

HY-B0148S

Risedronic Acid-d4	Isotope-Labeled Compounds	Others
Risedronic Acid-d₄ is the deuterium labeled Risedronic acid. Risedronic acid (Risedronate) is a pyridinyl biphosphonate which inhibits osteoclast-mediated bone resorption[1][2].

HY-N5023

Veraguensin

Others Metabolic Disease

Veraguensin is a lignan compound derived from Magnolia sp.. Veraguensin can inhibit bone resorption

Veraguensin	Others	Metabolic Disease
Veraguensin is a lignan compound derived from Magnolia sp.. Veraguensin can inhibit bone resorption

HY-B0657A

Clodronic acid disodium salt Clodronate disodium salt
Clodronic acid (Clodronate) disodium salt, a first-generation bisphosphonate, is orally active osteoclastic bone resorption inhibitor. Clodronic acid disodium salt can be used in high bone turnover states, Paget ^’s disease and osteolytic bone metastases .

HY-108685

Alendronate sodium Alendronic acid monosodium salt	Others	Metabolic Disease
Alendronate sodium is an orally active nitrogen-containing bisphosphonate. Alendronate sodium potently inhibits bone resorption. Alendronate sodium is used for the research of postmenopausal osteoporosis .

HY-P4684

Osteostatin PTHrP (107–111)	PTHR
Osteostatin, a fragment of parathyroid hormone-related protein (PTHrP) 107-111, promotes bone repair in animal models of bone defects and prevents bone erosion in inflammatory arthritis, inhibits collagen-induced arthritis and inhibits osteoclastic bone resorption directly. Osteostatin can be used for inflammation and immunology research .

HY-N0094R

Ipriflavone (Standard)	Others	Metabolic Disease Cancer
Ipriflavone (Standard) is the analytical standard of Ipriflavone. This product is intended for research and analytical applications. Ipriflavone is a synthetic isoflavone derivative used to suppress bone resorption.

HY-148698

2MD	VD/VDR	Others
2MD is an orally active vitamin D analog. 2MD stimulates periosteal bone formation and decreases trabecular bone resorption. Thus 2MD restores trabecular and cortical bone mass and strength. 2MD also regulates intraocular pressure (IOP)-relative genes and reduces IOP in non-human primates .

HY-N10117

2,3-Bis(3-indolylmethyl)indole	RANKL/RANK	Others
2,3-Bis(3-indolylmethyl)indole significantly suppresses RANKL-induced osteoclast formation, actin ring formation, and bone resorption in a concentration-dependent manner.

HY-17397

Strontium Ranelate 2 Publications Verification Distrontium renelate; S12911	CaSR	Metabolic Disease
Strontium Ranelate (S12911) is an antiosteoporotic agent that acts by reducing bone resorption and promoting bone formation, thereby inducing a positive bone balance. Strontium Ranelate can also activate the calcium-sensing receptor (CaSR) in non skeletal cells, resulting in the activation of inositol 1, 4, 5-triphosphate production and mitogen-activated protein kinase signaling .

HY-B0631

Alendronic acid 2 Publications Verification	Others	Cancer
Alendronic acid, a bisphosphonate, is a farnesyl diphosphate synthase (FDPS) inhibitor. Alendronic acid inhibits osteoclast-mediated bone resorption. Alendronic acid shows efficacy in postmenopausal osteoporosis, malignant hypercalcemia and Paget’s disease .

HY-N7646

Curculigoside B	Others	Others
Curculigoside B, a phenolic glycoside isolated from Curculigo orchioides, enhances the osteoblast proliferation, decreases the area of bone resorption pit, osteoclastic formation and TRAP activity. Antiosteoporotic and antioxidative activities .

HY-P4798

Osteostatin (1-5) amide (human, bovine, dog, horse, mouse, rabbit, rat) Human PTHrP(107-111) amide	PTHR	Others
Osteostatin (1-5) amide (human, bovine, dog, horse, mouse, rabbit, rat) (Human PTHrP (107-111) amide) is a C-terminal parathyroid hormone-related protein fragment that can inhibit bone resorption .

HY-B1246

Thonzonium bromide 5 Publications Verification	Bacterial Proton Pump	Infection
Thonzonium bromide is an antibacterial agent that is structurally similar to Farnesol (HY-Y0248A). Thonzonium bromide is also a monocationic surface-active agent, which inhibits RANKL-induced osteoclast formation and bone resorption in vitro and prevents LPS-induced bone loss in vivo. Thonzonium bromide inhibits proton transport in a dose-dependent manner (EC₅₀=69 μM) .

HY-B0631S

Alendronic acid-d6	Isotope-Labeled Compounds	Cancer
Alendronic acid-d₆ is the deuterium labeled Alendronic acid. Alendronic acid, a bisphosphonate, is a farnesyl diphosphate synthase (FDPS) inhibitor. Alendronic acid inhibits osteoclast-mediated bone resorption. Alendronic acid shows efficacy in postmenopausal osteoporosis, malignant hypercalcemia and Paget’s disease[1].

HY-B0302

Etidronic acid 1 Publications Verification Etidronate; HEDPA; HEDP	Apoptosis	Metabolic Disease Cancer
Etidronic acid (Etidronate) is an orally and intravenously active bisphosphonate. Etidronic acid inhibits resorption of bone, reduces arterial calcification and can be used for osteoporosis research. Etidronic acid has anticancer activity. Etidronic acid is a chelating agent and can be used to remove heavy metal in water .

HY-P4817

Human PTH-(1-31)	Thyroid Hormone Receptor	Metabolic Disease
Human PTH-(1-31) is the 1-31 fragment of human PTH. Human PTH-(1-31) stimulates the release of cAMP and also is a weaker stimulator of the 25-hydroxyvitamin D-1α-hydroxylase. Human PTH-(1-31) induces bone formation without inducing bone resorption. Human PTH-(1-31) has the potential for the research of osteoporosis .

HY-N1956

Rubiadin-1-methyl ether
Rubiadin-1-methyl ether is a natural anthraquinone isolated from Morinda officinalis How, and inhibits osteoclastic bone resorption via inhibition on the phosphorylation of NF-κB p65 and the degradation of IκBα as well as decrease in the nuclear translocation of p65 .

HY-119868

Butaxamine Butoxamin	Adrenergic Receptor	Metabolic Disease
Butaxamine (Butoxamin) is a potent, selective and orally active β2-adrenoceptor antagonist. Butaxamine shows antiosteoporotic activity .

HY-A0020S

Eldecalcitol-d6	VD/VDR	Metabolic Disease
Eldecalcitol-d₆ is the deuterium labeled Eldecalcitol. Eldecalcitol is an orally active analogue of active vitamin D used in the treatment of osteoporosis.

HY-B0302A

Etidronic acid disodium 1 Publications Verification Etidronate disodium; HEDPA disodium; HEDP disodium
Etidronic acid (Etidronate) disodium is an orally and intravenously active bisphosphonate. Etidronic acid disodium inhibits resorption of bone, reduces arterial calcification and can be used for osteoporosis research. Etidronic acid disodium has anticancer activity. Etidronic acid disodium is a chelating agent and can be used to remove heavy metal in water .

Cat. No.	Product Name	Target	Research Area

HY-P2273

Calcitonin (human)	CGRP Receptor	Metabolic Disease
Calcitonin (human) is a hypocalcemic hormone. Calcitonin can lower blood calcium levels and inhibit bone resorption. Calcitonin can be used in hypercalcemia or osteoporosis research .

HY-P1418A

DPC-AJ1951 TFA	Thyroid Hormone Receptor	Endocrinology
DPC-AJ1951 TFA, a 14 amino acid peptide that acts as a potent agonist of the parathyroid hormone (PTH)/PTH-related peptide receptor (PPR). And characterized the activity of DPC-AJ1951 TFA in ex vivo and in vivo assays of bone resorption .

HY-P1288

Protein Kinase C (530-558) PKC fragment (530-558)	PKC	Others
Protein Kinase C (530-558), a peptide fragment of protein kinase C (PKC), is a potent PKC activator. Protein Kinase C (530-558) significantly inhibits osteoclastic bone resorption .

HY-P0007

Elcatonin Carbocalcitonin	Peptides	Metabolic Disease
Elcatonin (Carbocalcitonin) is a synthetic analog of eel calcitonin. Elcatonin increases bone mineral density, inhibits bone resorption and processes a central analgesic effect .

HY-P1418

DPC-AJ1951	Thyroid Hormone Receptor	Endocrinology
DPC-AJ1951, a 14 amino acid peptide that acts as a potent agonist of the parathyroid hormone (PTH)/PTH-related peptide receptor (PPR). And characterized the activity of DPC-AJ1951 in ex vivo and in vivo assays of bone resorption .

HY-P0322

GRGDSPK EMD 56574	Integrin	Cardiovascular Disease Metabolic Disease
GRGDSPK (EMD 56574) is a peptide incluing Arg-Gly-Asp (RGD). GRGDSPK (EMD 56574) is an competitive and reversible inhibitory peptide for inhibiting integrin-fibronectin binding. GRGDSPK is used to study the role of integrins in bone formation and resorption .

HY-P0322A

GRGDSPK TFA EMD 56574 TFA	Integrin	Cardiovascular Disease Metabolic Disease
GRGDSPK TFA (EMD 56574 TFA) is a peptide incluing Arg-Gly-Asp (RGD). GRGDSPK TFA is an competitive and reversible inhibitory peptide for inhibiting integrin-fibronectin binding. GRGDSPK TFA is used to study the role of integrins in bone formation and resorption .

HY-P0090

Calcitonin (salmon) 1 Publications Verification Salmon calcitonin	CGRP Receptor	Cancer
Calcitonin salmon, a calcium regulating hormone, is a dual-action amylin and calcitonin receptor agonist, could stimulate bone formation and inhibit bone resorption.

HY-P0284

C-telopeptide	Peptides	Inflammation/Immunology
C-telopeptide, a cross-linked peptide of type I collagen, is released during bone resorption and has been correlated with bone mineral density (BMD).

HY-P4684

Osteostatin PTHrP (107–111)	PTHR
Osteostatin, a fragment of parathyroid hormone-related protein (PTHrP) 107-111, promotes bone repair in animal models of bone defects and prevents bone erosion in inflammatory arthritis, inhibits collagen-induced arthritis and inhibits osteoclastic bone resorption directly. Osteostatin can be used for inflammation and immunology research .

HY-P4798

Osteostatin (1-5) amide (human, bovine, dog, horse, mouse, rabbit, rat) Human PTHrP(107-111) amide	PTHR	Others
Osteostatin (1-5) amide (human, bovine, dog, horse, mouse, rabbit, rat) (Human PTHrP (107-111) amide) is a C-terminal parathyroid hormone-related protein fragment that can inhibit bone resorption .

HY-P4817

Human PTH-(1-31)	Thyroid Hormone Receptor	Metabolic Disease
Human PTH-(1-31) is the 1-31 fragment of human PTH. Human PTH-(1-31) stimulates the release of cAMP and also is a weaker stimulator of the 25-hydroxyvitamin D-1α-hydroxylase. Human PTH-(1-31) induces bone formation without inducing bone resorption. Human PTH-(1-31) has the potential for the research of osteoporosis .

HY-P1189

Echistatin	Integrin	Metabolic Disease Inflammation/Immunology
Echistatin, the smallest active RGD protein belonging to the family of disintegrins that are derived from snake venoms, is a potent inhibitor of platelet aggregation. Echistatin is a potent inhibitor of **bone resorption in culture. Echistatin is a potent antagonist of α_IIbβ₃, α_vβ₃ and α₅β₁** .

HY-P1189A

Echistatin TFA	Integrin	Metabolic Disease Inflammation/Immunology
Echistatin TFA, the smallest active RGD protein belonging to the family of disintegrins that are derived from snake venoms, is a potent inhibitor of platelet aggregation. Echistatin is a potent inhibitor of **bone resorption in culture. Echistatin is a potent antagonist of α_IIbβ₃, α_vβ₃ and α₅β₁** .

HY-P5377

Abz-HPGGPQ-EDDnp Cathepsin K substrate	Peptides	Others
Abz-HPGGPQ-EDDnp (Cathepsin K substrate) is a biological active peptide. (Cathepsins are a class of globular lysosomal proteases, playing a vital role in mammalian cellular turnover. They degrade polypeptides and are distinguished by their substrate specificities. Cathepsin K is the lysosomal cysteine protease involved in bone remodeling and resorption. It has potential as a drug target in autoimmune diseases and osteoporosis.This FRET peptide can be used to monitor selectively cathepsin K activity in physiological fluids and cell lysates. Abz-HPGGPQ-EDDnp [where Abz represents o-aminobenzoic acid and EDDnp represents N -(2, 4-dinitrophenyl)-ethylenediamine], a substrate initially developed for trypanosomal enzymes, is efficiently cleaved at the Gly-Gly bond by cathepsin K. This peptide is resistant to hydrolysis by cathepsins B, F, H, L, S and V, Ex/Em=340 nm/420 nm.)

Cat. No.	Product Name	Category	Target	Chemical Structure